EOM Pharmaceuticals

EOM Pharmaceuticals is a clinical-stage biotech focused on developing novel therapies for inflammatory and retinal diseases. Its core strategy leverages a unique peptide-nucleic acid (PNA) platform, exemplified by lead candidate EOM613, which aims to dynamically modulate the immune system to address cytokine-driven pathologies. The company has advanced EOM613 into Phase 1/2 clinical testing in COVID-19 and is developing a second asset, EOM147, as a topical eye drop for retinal diseases. EOM's mission is to 'rescue, repair, and restore health' by transforming therapeutic paradigms in areas of high unmet need.

A peptide-nucleic acid (PNA) platform designed to create dynamically dual-acting immunomodulators that can suppress or stimulate immune responses based on cellular context, aiming to restore immune homeostasis rather than cause blanket immunosuppression.

In immunomodulation, EOM613 competes against approved suppressive therapies like IL-6 and JAK inhibitors, differentiating on its proposed dynamic action. In retinal disease, EOM147 faces dominant anti-VEGF injectables and must prove a topical formulation can achieve comparable efficacy, a challenge where many others have failed.